

As a healthcare group giving people the closest possible support, we do everything in our power to positively impact all aspects of society.

In the 43 years since its founding, Nihon Chouzai has continued to evolve into a healthcare group that gives people the closest possible support. We are now in the fourth year since the 2020 outbreak of COVID-19. Over this period, the business portfolio of the Nihon Chouzai Group, made up of four healthcare businesses, has grown steadily despite drastic changes in the business environment. Japan's healthcare system is currently entering a period of major upheaval, sparked in large part by government efforts to overhaul the system, promote the digital transformation of healthcare, and revise medical treatment fees. I am convinced that our ability to stay abreast of such changes and continue to lead the industry rests in the steady commitment of all of our officers and employees to fulfill our mission of giving people the closest possible support. Even in this time of mounting uncertainties, including developments in overseas situations, soaring prices, and the increasing frequency of natural disasters worldwide, we cannot stop providing healthcare to patients. I am proud of how the pharmacists and other medical professionals who are part of the Nihon Chouzai Group are drawing on their expertise as medical personnel to pursue their high calling of contributing to Japan's regional healthcare.

Management is Also Embracing the Challenge of Major Reforms.

After unveiling our new Group philosophy in April last year, we announced plans to revise the long-term vision for 2030 in April 2023. We sensed the need to formulate management

Yosuke Mitsuvara

President and CEO

Mitsuvara joined Nihon Chouzai in 1999. Having served as General Manager of the Corporate Planning Department, Subsidiary Director, Managing Director, and Senior Managing Director, Mitsuvara became President and CEO of the Company in 2019. With thorough knowledge of ICT, he spearheaded development of the Company's electronic medication notebook and has implemented company-wide digital transformation initiatives. With an MBA from Waseda University Graduate School and a master's degree from Johns Hopkins University Bloomberg School of Public Health, he is contributing to management from both management and medical perspectives.

strategies that reflect current public healthcare policy and the business environment, which have both changed significantly since we first formulated the vision in 2018. Furthermore, societal expectations are mounting for us as a listed company in the wake of our re-listing on the Prime Market of the Tokyo Stock Exchange after it reorganized its markets. To meet stakeholder expectations, we are exploring a more comprehensive vision that includes aspects such as corporate governance, financial strategy, and sustainability management. We will also disclose medium-term management strategies for achieving the long-term vision, addressing the expectations of our investors and shareholders by clearly laying out the long-term vision and the path to achieving it.

